Venlafaxine STELLA

Venlafaxine STELLA Liều dùng/Hướng dẫn sử dụng

venlafaxine

Nhà sản xuất:

Stellapharm

Nhà phân phối:

Khuong Duy
Thông tin kê toa chi tiết tiếng Anh
Dosage/Direction for Use
Major depressive episodes: The recommended starting dose is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more.
Generalised anxiety disorder: The recommended starting dose is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 225 mg/day. Dosage increases can be made at intervals of 2 weeks or more.
Social anxiety disorder: The recommended dose is 75 mg given once daily. There is no evidence that higher doses confer any additional benefit.
However, in individual patients not responding to the initial 75 mg/day, increases up to a maximum dose of 225 mg/day may be considered. Dosage increases can be made at intervals of 2 weeks or more.
Panic disorder: It is recommended that a dose of 37.5 mg/day be used for 7 days. Dosage should then be increased to 75 mg/day. Patients not responding to the 75 mg/day dose may benefit from dose increases up to a maximum dose of 225 mg/day. Dosage increases can be made at intervals of 2 weeks or more.
Prevention of recurrence of major depressive episodes: Capsule: Longer term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during the current episode.
Use in elderly patients: Caution should be exercised in treating the elderly. The lowest effective dose should always be used, and patients should be carefully monitored when an increase in the dose is required.
Use in patients with hepatic/renal impairment: Capsule: Because of inter-individual variability in clearance in these patients, individualisation of dosage may be desirable.
Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation. The lowest effective dose should be maintained.
Use in patients with hepatic impairment: MR-FC Tablet: In patients with mild and moderate hepatic impairment, in general a 50% dose reduction should be considered.
The potential benefit should be weighed against the risk in the treatment of patients with severe hepatic impairment.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in